In a report released yesterday, Jay Olson from Oppenheimer maintained a Buy rating on TherapeuticsMD (NYSE MKT: TXMD), with a price target of $14. The company’s shares closed yesterday at $6.71.
Olson noted:
“We met management for an update on Imvexxy and plans for the potential TX-001HR and Annovera launches next year. The Imvexxy launch continues to impress with an initial trajectory on track to double the uptake of the most recent competitive launch (Exhibit 2). With the Oct. 28 TX-001HR PDUFA just over one month away, we suspect the company could enter FDA label negotiations by next week and may issue a press release to that effect assuming a quiet period would ensue. We continue to view TX-001HR as a significant opportunity with ~2x the peak sales potential compared to Imvexxy and, therefore, the dominant value driver for TXMD shares while Annovera represents an under-appreciated source of additional upside. Details inside.”
According to TipRanks.com, Olson is a 1-star analyst with an average return of 0.0% and a 46.2% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Eiger Biopharmaceuticals, and Conatus Pharmaceuticals.
TherapeuticsMD has an analyst consensus of Strong Buy, with a price target consensus of $20.33.
See today’s analyst top recommended stocks >>
Based on TherapeuticsMD’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $33.22 million. In comparison, last year the company had a GAAP net loss of $19.68 million.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TXMD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.
Read More on TXMD:
